GlassScriptPhysician profile
Alan P Baptist
NPI 1043257751
$167,930.49
in general payments reported to CMS, 2019-2025
26 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,438 · 2020: $1,300 · 2021: $15K · 2022: $22K · 2023: $57K · 2024: $23K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Travel and Lodging: $7,229 · Food and Beverage: $6,281 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,510.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,000.00 |
| Travel and Lodging | $7,228.96 |
| Food and Beverage | $6,281.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $880.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62,262.23 | 2020-2025 | Trelegy Ellipta, Nucala |
| Csl Behring | $27,304.59 | 2019-2025 | Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $21,783.90 | 2022-2025 | Takhzyro, Eohilia |
| Astrazeneca Pharmaceuticals LP | $14,082.18 | 2019-2025 | Airsupra, Fasenra |
| Biocryst Pharmaceuticals, INC. | $11,270.66 | 2019-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $9,506.19 | 2019-2025 | Airduo Digihaler, Armonair Digihaler, Proair Digihaler |
| Sanofi US Services INC. | $4,537.73 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $4,344.14 | 2025 | Dupixent |
| Biocryst US Sales Co., LLC | $3,134.53 | 2021-2024 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $2,588.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,461.29 | 2024-2025 | Dupixent |
| Alk-Abello, INC | $1,773.25 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $1,034.00 | 2022 | |
| Genentech USA, INC. | $880.00 | 2024 | Xolair |
| Genzyme Corporation | $484.40 | 2023-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $165.42 | 2022-2023 | Xolair |
| Aquestive Therapeutics, INC. | $119.22 | 2025 | |
| Optinose US, INC. | $89.67 | 2022 | |
| Blueprint Medicines Corporation | $46.13 | 2025 | Ayvakit |
| Amgen INC. | $46.05 | 2023-2025 | Tezspire |
| Pharming Healthcare, INC. | $16.79 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Baptist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.